Rabbit Polyclonal CYP2A6 Antibody

The cytochrome P450 2A6 (CYP2A6) enzyme, encoded by the *CYP2A6* gene, plays a critical role in metabolizing various xenobiotics, including nicotine, tobacco-derived nitrosamines, and certain pharmaceuticals (e.g., valproic acid). CYP2A6 antibodies are immunological tools designed to detect and quantify this enzyme in biological samples. These antibodies are essential for studying CYP2A6 expression patterns, tissue distribution, and regulatory mechanisms, particularly in the liver and respiratory tract. Research has linked *CYP2A6* genetic polymorphisms to interindividual variability in drug metabolism efficiency, addiction susceptibility (e.g., nicotine dependence), and cancer risk (e.g., lung or liver cancer). Specific CYP2A6 antibodies—monoclonal or polyclonal—enable techniques like Western blotting, immunohistochemistry, and enzyme activity assays. Their applications extend to pharmacogenomics, toxicology, and personalized medicine, where understanding CYP2A6 variability helps predict drug responses or detoxification capacities. Recent studies also explore CYP2A6's role in activating prodrugs or metabolizing environmental carcinogens, emphasizing the antibody's utility in mechanistic and translational research. However, challenges remain in ensuring antibody specificity due to homology among CYP isoforms. Validated antibodies are critical for accurate experimental outcomes, supporting advancements in disease biomarker discovery and therapeutic targeting.